기업 정보 불러오는 중
Just reported
Q2 FY2027 results
From Mckesson's results release of 2026년 11월 4일; its quarterly report has since been filed.
Revenue
Actual
US$110.96B
+7.6% y/y
+5.3% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$10.44
+17% y/y
+103% q/qGuided
—
No guide given
EPS, adjusted: US$11.68
Operating income, GAAP
Actual
US$1.6B
+14% y/y
+22% q/qGuided
—
No guide given
Company outlook
Full year 2027
- EPS, adjustedUS$45.60 – US$46.40Raised +3.1%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Mckesson is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026년 10월 21일CBGraded C, now B
CVSCVS Health Corp2026년 11월 4일BAGraded B, now A
EWEdwards Lifesciences Corporation2026년 11월 4일BAGraded B, now A
BIIBBiogen Inc.2026년 10월 28일BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026년 10월 28일CAGraded C, now A
어떻게 돈을 버는가
- Prescription-drug distribution in the United States and Canada84%
- Oncology and multispecialty distribution and provider services12%
- Medical, surgical, and laboratory distribution3%
- Prescription technology and biopharmaceutical services1%
매출 비중은 FY2026 ended 2026-03-31 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.
경쟁 상대
무엇을 파는가6
Prescription-drug distribution
Wholesale supply and delivery of branded, generic, specialty, biosimilar, and over-the-counter medicines to pharmacies and health providers.
Pharmacy business services
Financial, operational, clinical, consulting, and technology services for retail, hospital, and other pharmacies.
Oncology and multispecialty provider services
Specialty-drug distribution, infusion services, direct-to-patient pharmacy services, and support for community oncology and other specialty-care practices.
3개 더 보기
Prescription access and affordability services
Services that help check insurance coverage, obtain prior authorization, compare prescription prices, support dispensing, and enroll patients in assistance programs.
Biopharmaceutical logistics and distribution
Storage, transport, and distribution services for biopharmaceutical manufacturers, including products requiring temperature-controlled handling.
Medical, surgical, and laboratory supplies
Distribution of branded and McKesson's own medical, surgical, and laboratory products to care providers outside acute-care hospitals.
누가 사는가5
- Retail and hospital pharmacies buy medicines and pharmacy services.
- Hospitals and other institutional health providers buy medicines, including specialty drugs.
- Oncology and multispecialty practices use drug distribution, practice support, infusion, and related services.
2개 더 보기
- Biopharmaceutical manufacturers use logistics, distribution, and patient access services.
- Physician offices, surgery centers, nursing homes, hospice providers, and home health agencies buy medical and surgical supplies.
무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가
사업이 기대고 있는 것
- 1Drug distribution depends on manufacturers supplying medicines and on manufacturer pricing, which can change the reported value of sales.
- 2Operations depend on information systems and networks for distribution, customer services, and technology products.
- 3Changes to drug-pricing rules, the federal 340B Drug Pricing Program, or government funding of health care can affect the pharmaceutical supply chain and McKesson's services.
잘못될 수 있는 일
- 1Cybersecurity incidents could compromise McKesson's technology systems or expose sensitive data.
- 2Problems with information systems or networks, or technology products that do not work as intended, could disrupt operations or customer services.
- 3Changes in government health policy, drug pricing, the 340B Drug Pricing Program, or government funding could affect the company's operations and participants in the pharmaceutical supply chain.
Mckesson Corporation 소개
McKesson buys medicines from manufacturers and sells and delivers them to pharmacies, hospitals, and other care providers. It also distributes specialty medicines and supports community oncology practices with services, research, and technology. Its prescription services help connect patients, pharmacies, providers, health plans, and drug manufacturers to handle coverage checks, prior authorization, and affordability programs. It also supplies medical, surgical, and laboratory products to care providers outside hospitals.
- 본사
- Irving, Texas, United States
- 설립
- 1833 (year founded, high confidence)
- 임직원 수
- 43,000 (FY2026, high)
- 상장 시장
- New York Stock Exchange
- 회계연도 종료
- March 31
Mckesson Corporation이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
